首页/数据集/Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Supplementary Material.

Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Supplementary Material.

NIAID Data Ecosystem2026-03-14 收录

肺癌免疫治疗

胸部肿瘤研究

数据链接：

https://figshare.com/articles/dataset/Immune_checkpoint_inhibitors_in_lung_tumors_with_rare_histologies_and_other_thoracic_malignancies_Supplementary_Material_/21563961 数据链接链接失效反馈

官方服务：

资源简介：

Case reports/series.

应用场景：

创建时间：

2022-11-16

肺癌免疫治疗

CD137靶向疗法

Negative immune regulation plays a notable role in tumor immunity. This study aimed to confirm that CD137 mediates negative immunoregulation as well as agonist activity in tumor immunity. Soluble CD13

NIAID Data Ecosystem70

2016-2020年ICIs治疗肺癌活检组织转录组测序数据

肺癌免疫治疗

生物标志物

以抗PD-1/PD-L1为代表的免疫检查点抑制剂在晚期肺癌治疗中取得显著疗效，然而临床研究结果显示只有20%左右患者从免疫单药治疗中获益，因此如何有效预测免疫治疗疗效具有重要意义。本项目收集临床免疫检查点抑制剂治疗晚期肺癌患者肿瘤组织，利用转录组测序技术检测肿瘤组织转录组，结合临床疗效探索可以预测免疫治疗疗效的生物标志物。

国家人口健康科学数据中心40

Table_2_Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer.DOCX

肺癌免疫治疗

CD11b靶向药物

Lung cancer is one of the leading causes of cancer-related deaths in the United States. A major hurdle for improved therapies is immune suppression mediated by the tumor and its microenvironment. The

NIAID Data Ecosystem20

Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

肺癌免疫治疗

PD-L1表达分析

Table S1 Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching Table S2 Landmark analysis of overall su

DataCite Commons2022-05-03 更新60

Supplementary Tables 1 from Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade

肺癌免疫治疗

基因突变分析

Tables S1-S4

Figshare2025-01-17 更新30